HRP20080077T3 - Substituted n-cyclohexylimidazolinones having an mch-modulatory effect - Google Patents

Substituted n-cyclohexylimidazolinones having an mch-modulatory effect

Info

Publication number
HRP20080077T3
HRP20080077T3 HR20080077T HRP20080077T HRP20080077T3 HR P20080077 T3 HRP20080077 T3 HR P20080077T3 HR 20080077 T HR20080077 T HR 20080077T HR P20080077 T HRP20080077 T HR P20080077T HR P20080077 T3 HRP20080077 T3 HR P20080077T3
Authority
HR
Croatia
Prior art keywords
alkyl
group
independently
another
alkoxy
Prior art date
Application number
HR20080077T
Other languages
Croatian (hr)
Inventor
Schwink Lothar
Boehme Thomas
Gossel Matthias
Stengelin Siegfried
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of HRP20080077T3 publication Critical patent/HRP20080077T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Spoj formule I, u kojoj su oznakeR1 H, (C1-C8)-alkil, (C1-C4)-alkoksi-(C1-C4)-alkil, (C3-C8)-alkenil, (C3-C8)-alkinil, 3 do 10-člani mono, bi- ili spirociklički prsten koji može uključiti 0 do 4 heteroatoma izabranih iz skupine kisika, dušika i sumpora, gdje sustav prstena može dodatno biti supstituiran s F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkil, O-(C1-C8)-alkil, S-(C1-C8)-alkil, (C1-C4)-alkoksi-(C1-C4)-alkil, (C0-C8)-alkilen-aril, okso, CO(R3), CON(R4)(R5), hidroksi, hidroksi-(C1-C4)-alkil, COO(R6), N(R7)CO(C1-C6)-alkil, N(R8)(R9) ili SO2CH3; R3, R4, R5, R6, R7, R8, R9, neovisno jedan od drugog H, (C1-C6)-alkil; K skupina formule -(CR10R11)z-u kojoj jedna ili više -(CR10R11)- skupina može biti zamijenjena s Z, veza, CşC, C=C; Z O, CO, N(R59), S, SO, SO2;R10, R11 neovisno jedan od drugog H, (C1-C8)-alkil, hidroksi-(C1-C4)-alkil, hidroksi,(C1-C4)-alkoksi-(C1-C4)-alkil, gdje R10 i R11 u zskupinama mogu u svakom slučaju imati ista ili različita značenja; z 1, 2, 3, 4, 5, 6; R59 H, (C1-C8)-alkil; E 3-14-člana bivalentna karbo- ili heterociklička prstenasta struktura koja ima 0-4 heteroatoma iz skupine N, O i S, koji po izboru mogu imati supstituente iz skupine H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, okso, O-(C1-C6)-alkil, O-(C1-C4)-alkoksi-(C1-C4)-alkil, S-(C1-C6)-alkil, (C1-C6)-alkil, (C2-C6)-alkenil, (C3-C8)cikloalkil, O-(C3-C8)cikloalkil, (C3-C8)cikloalkenil, O-(C3-C8)cikloalkenil, (C2-C6)-alkinil, (C0-C8)-alkilen-aril, O-(C0-C8)-alkilen-aril, S-aril, N(R12)(R13), SO2-CH3, COOH, COO-(C1-C6)-alkil, CON(R14)(R15), N(R16)CO(R17), N(R18)SO2(R19), CO(R20) i biti mono ili biciklički; R12, R13, R14, R15, R16, R18 neovisno jedanod drugog H, (C1-C8)-alkil; ili R12 i R13, R14 i R15 neovisno jedan od drugog, po izboru zajedno s dušikovim atomom za koji su vezani, 5-6-člani prsten koji, osim dušikovog atoma, može također uključiti 0-1 daljnjih heteroatoma iz skupine N-(C1-C6)-alkil, kisik i sumpor; R17, R19, R20 neovisno jedan od drugog H, (C1-C8)-alkil, aril; X veza, skupina formule -(CR21R22)y-, u kojoj jedna ili više -(CR21R22)- skupina može biti zamijenjena s Y; Y O, CO, N(R23), S, SO, SO2;R21, R22 neovisno jedan od drugog H, (C1-C4)-alkil, gdje R21 i R22 u y skupinama mogu u svakom slučaju imati ista ili različita značenja; y 1, 2, 3, 4, 5, 6; R23 H, (C1-C8)-alkil; D, G CH ili N; R2 OH, O-(C1-C6)-alkil, O-(C1-C4)-alkoksi-(C1-C4)-alkil, (C1-C6)-alkil; n 0, 1, 2, 3, 4; Q N(R24)(R25), 3 do 8-člani prsten koji možeuključiti 0 do 3 heteroatoma izabranih iz skupinekisik, dušik i sumpor gdje sustav prstena može dodatno biti zamijenjen s (C0-C4)-alkilen-N(R24)(R25), F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkil, O-(C1-C8)-alkil, (C1-C4)-alkoksi-(C1-C4)-alkil, (C0-C8)-alkilen-aril, okso, CO(R26), CON(R27)(R28), hidroksi, hidroksi-(C1-C4)-alkil, COO(R29), N(R30)CO(C1-C6)-alkil ili SO2CH3;R26, R27, R28, R29, R30 neovisno jedan od drugog H, (C1-C6)-alkil; A skupina formule -(C(R31)(R32))m-, u kojoj 0-2 člana mogu bitizamijenjeni s elementom iz skupine O, S, N(R33), CO, SO2;A compound of formula I, wherein R1 is H, (C1-C8) -alkyl, (C1-C4) -alkoxy- (C1-C4) -alkyl, (C3-C8) -alkenyl, (C3-C8) -alkynyl, 3 to 10 membered mono, bi- or spirocyclic ring which may include 0 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where the ring system may be further substituted by F, Cl, Br, CF3, NO2, CN, (C1 -C6) -alkyl, O- (C1-C8) -alkyl, S- (C1-C8) -alkyl, (C1-C4) -alkoxy- (C1-C4) -alkyl, (C0-C8) -alkylene- aryl, oxo, CO (R3), CON (R4) (R5), hydroxy, hydroxy- (C1-C4) -alkyl, COO (R6), N (R7) CO (C1-C6) -alkyl, N ) (R9) or SO2CH3; R3, R4, R5, R6, R7, R8, R9, independently of one another H, (C1-C6) -alkyl; K is a group of formula - (CR10R11) z-wherein one or more - (CR10R11) - groups may be replaced by Z, a bond, CşC, C = C; ZO, CO, N (R59), S, SO, SO2, R10, R11 independently of one another H, (C1-C8) -alkyl, hydroxy- (C1-C4) -alkyl, hydroxy, (C1-C4) - alkoxy- (C1-C4) -alkyl, wherein R10 and R11 in the z groups may in each case have the same or different meanings; z 1, 2, 3, 4, 5, 6; R59 H, (C1-C8) -alkyl; E is a 3-14 membered bivalent carbo- or heterocyclic ring structure having 0-4 heteroatoms from the group N, O and S, which may optionally have substituents from the group H, F, Cl, Br, I, OH, CF3, NO2 , CN, OCF3, oxo, O- (C1-C6) -alkyl, O- (C1-C4) -alkoxy- (C1-C4) -alkyl, S- (C1-C6) -alkyl, (C1-C6) -alkyl, (C2-C6) -alkenyl, (C3-C8) cycloalkyl, O- (C3-C8) cycloalkyl, (C3-C8) cycloalkenyl, O- (C3-C8) cycloalkenyl, (C2-C6) -alkynyl , (C0-C8) -alkylene-aryl, O- (C0-C8) -alkylene-aryl, S-aryl, N (R12) (R13), SO2-CH3, COOH, COO- (C1-C6) -alkyl , CON (R14) (R15), N (R16) CO (R17), N (R18) SO2 (R19), CO (R20) and be mono or bicyclic; R12, R13, R14, R15, R16, R18 independently of one another H, (C1-C8) -alkyl; or R12 and R13, R14 and R15 independently of one another, optionally together with the nitrogen atom to which they are attached, a 5-6 membered ring which, in addition to the nitrogen atom, may also include 0-1 further heteroatoms from the group N- (C1 -C6) -alkyl, oxygen and sulfur; R17, R19, R20 independently of one another H, (C1-C8) -alkyl, aryl; X is a bond, a group of formula - (CR21R22) y-, in which one or more - (CR21R22) - groups may be replaced by Y; Y O, CO, N (R23), S, SO, SO2, R21, R22 independently of one another H, (C1-C4) -alkyl, where R21 and R22 in the y groups may in each case have the same or different meanings; y 1, 2, 3, 4, 5, 6; R23 is H, (C1-C8) -alkyl; D, G CH or N; R2 is OH, O- (C1-C6) -alkyl, O- (C1-C4) -alkoxy- (C1-C4) -alkyl, (C1-C6) -alkyl; n is 0, 1, 2, 3, 4; QN (R24) (R25), a 3 to 8 membered ring which may include 0 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur where the ring system may be further replaced by (C0-C4) -alkylene-N (R24) (R25) , F, Cl, Br, CF3, NO2, CN, (C1-C6) -alkyl, O- (C1-C8) -alkyl, (C1-C4) -alkoxy- (C1-C4) -alkyl, (C0- C8) -alkylene-aryl, oxo, CO (R26), CON (R27) (R28), hydroxy, hydroxy- (C1-C4) -alkyl, COO (R29), N (R30) CO (C1-C6) - alkyl or SO2CH3; R26, R27, R28, R29, R30 independently of one another H, (C1-C6) -alkyl; A group of the formula - (C (R31) (R32)) m-, in which 0-2 members can be replaced by an element from the group O, S, N (R33), CO, SO2;

HR20080077T 2004-01-25 2008-02-22 Substituted n-cyclohexylimidazolinones having an mch-modulatory effect HRP20080077T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004003811A DE102004003811A1 (en) 2004-01-25 2004-01-25 Substituted N-cyclohexylimidazolinones, processes for their preparation and their use as medicaments
PCT/EP2005/000700 WO2005070898A1 (en) 2004-01-25 2005-01-25 Substituted n-cyclohexyl imidazolinones having an mch-modulatory effect

Publications (1)

Publication Number Publication Date
HRP20080077T3 true HRP20080077T3 (en) 2008-03-31

Family

ID=34745115

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20080077T HRP20080077T3 (en) 2004-01-25 2008-02-22 Substituted n-cyclohexylimidazolinones having an mch-modulatory effect

Country Status (26)

Country Link
EP (1) EP1711473B1 (en)
JP (1) JP2007518771A (en)
KR (1) KR20060128955A (en)
CN (1) CN1934090B (en)
AR (1) AR047453A1 (en)
AT (1) ATE383342T1 (en)
AU (1) AU2005206308A1 (en)
BR (1) BRPI0507104A (en)
CA (1) CA2554233A1 (en)
CY (1) CY1107429T1 (en)
DE (2) DE102004003811A1 (en)
DK (1) DK1711473T3 (en)
ES (1) ES2297667T3 (en)
HR (1) HRP20080077T3 (en)
IL (1) IL176917A0 (en)
MA (1) MA28345A1 (en)
MY (1) MY139107A (en)
NO (1) NO20063757L (en)
PE (1) PE20051091A1 (en)
PL (1) PL1711473T3 (en)
PT (1) PT1711473E (en)
RS (1) RS50543B (en)
RU (1) RU2006130626A (en)
TW (1) TW200604182A (en)
UY (1) UY28726A1 (en)
WO (1) WO2005070898A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008129679A (en) 2005-12-21 2010-01-27 Янссен Фармацевтика Н.В. (Be) NEW SUBSTITUTED PYRAZINONIC DERIVATIVES FOR USE IN SIT-1-MEDIATED DISEASES
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
JP5290192B2 (en) 2006-12-05 2013-09-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Novel substituted diaza-spiro-pyridinone derivatives for use in diseases mediated by MCH-1
KR100893394B1 (en) * 2007-05-11 2009-04-17 한국화학연구원 Imidazole derivatives having aryl piperidine substituents, method for the preparation thereof, and pharmaceutical compositions containing them
AR072707A1 (en) 2008-07-09 2010-09-15 Sanofi Aventis HETEROCICLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, DRUGS THAT UNDERSTAND THESE COMPOUNDS AND THE USE OF THEM
DE102008060967A1 (en) * 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituted phenylsulfonyltriazolones and their use
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2683698B1 (en) 2011-03-08 2017-10-04 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
EP2683699B1 (en) 2011-03-08 2015-06-24 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683704B1 (en) 2011-03-08 2014-12-17 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
PL223830B1 (en) 2012-04-03 2016-11-30 Univ Jagielloński Derivatives of aromatic imidazolidinones and their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2468967A1 (en) * 2001-12-04 2003-06-12 Schering Corporation N-aryl-n'-arylcycloalkyl-urea derivatives as mch antagonists for the treatment of obesity
DE10233817A1 (en) * 2002-07-25 2004-02-12 Aventis Pharma Deutschland Gmbh Substituted diaryl heterocycles, process for their preparation and their use as medicaments

Also Published As

Publication number Publication date
PL1711473T3 (en) 2008-05-30
UY28726A1 (en) 2005-08-31
RS50543B (en) 2010-05-07
EP1711473A1 (en) 2006-10-18
DE502005002497D1 (en) 2008-02-21
JP2007518771A (en) 2007-07-12
MY139107A (en) 2009-08-28
WO2005070898A1 (en) 2005-08-04
ES2297667T3 (en) 2008-05-01
TW200604182A (en) 2006-02-01
NO20063757L (en) 2006-10-11
BRPI0507104A (en) 2007-06-19
PT1711473E (en) 2008-03-07
ATE383342T1 (en) 2008-01-15
MA28345A1 (en) 2006-12-01
DK1711473T3 (en) 2008-05-26
EP1711473B1 (en) 2008-01-09
CY1107429T1 (en) 2012-12-19
IL176917A0 (en) 2006-12-10
CA2554233A1 (en) 2005-08-04
CN1934090A (en) 2007-03-21
RU2006130626A (en) 2008-02-27
AR047453A1 (en) 2006-01-18
KR20060128955A (en) 2006-12-14
DE102004003811A1 (en) 2005-08-11
PE20051091A1 (en) 2006-01-23
CN1934090B (en) 2010-04-07
AU2005206308A1 (en) 2005-08-04

Similar Documents

Publication Publication Date Title
HRP20080077T3 (en) Substituted n-cyclohexylimidazolinones having an mch-modulatory effect
HRP20070421T3 (en) Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics
NO20091562L (en) 2-aryl-6-phenylimidazole {1,2-alpha} pyridine derivatives, five positions thereof, and therapeutic use thereof
HRP20050628A2 (en) Substituted benzoyl derivatives uses as herbicides
RS53682B1 (en) Pyrazinone derivatives and their use in the treatment of lung diseases
AR047974A1 (en) DERIVATIVES OF ALQUILPIPERAZINA AND ALQUILHOMOPIPERAZINA-CARBOXILATOS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
RS51743B (en) Macrocyclic inhibitors of hepatitis c virus
HUP0400989A2 (en) Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives, process for their preparation and pharmaceutical compositions containing them
AR040230A1 (en) INDOL, AZAINDOL, AND RELATED HETEROCICLES OF 4-ALQUENIL PIPERIDINA
RS53499B1 (en) Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
CO5580768A2 (en) DERIVATIVES OF 4,5-DIARILTIAZOL AS LIGANDOS CB-1
ATE191481T1 (en) INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS
NO20055204L (en) Derivatives of piperidinyl and pipemzinylalkylcarbamates, processes for their preparation and use of the same in therapy
RS51471B (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
HRPK20040930B3 (en) Acyl-4-carboxyphenylurea derivatives, method for production and use thereof
HRP20080541T3 (en) Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
AR066107A1 (en) DERIVATIVES OF TRIAZOLOPIRIDIN - CARBOXAMIDES AND TRIAZOLOPIRIMIDIN-CARBOXAMIDES, THEIR PREPARATION AND ITS APPLICATION IN THERAPEUTICS AS INHIBITORS OF THE GLICEROL LIPASA ENZYMAMONOACIL AND COMPOSITIONS CONTAINING THEM.
AR046080A1 (en) REPLACED PYRIDINONES
AR064414A1 (en) DERIVATIVES OF 1-AZONIABICICLO [2, 2, 2] OCTANO AND 1-AZABICICLO [2, 2, 2] OCT-3-ILO, A PROCESS FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, PROCEDURE FOR OBTAINING THE SAME, ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF COPD AND A PHARMACEUTICAL PRODUCT THAT
HUP0303825A2 (en) 1h-benzimidazole and 3h-imidazo-[4,5b]pyridine-derivatives, their use and pharmaceutical compositions containing them
ATE481456T1 (en) BLACK INKJET INK, INKJET RECORDING INK SET, INK CARTRIDGE, RECORDING UNIT AND INKJET RECORDING DEVICE
BR112015002017A2 (en) amide type compound
PE20081775A1 (en) MACROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA
HRP20090050T3 (en) Novel pyrrolidine-3,4-dicarboxamide derivatives
DK2032370T3 (en) Reversible thermochrome compositions